Highlights

  • Third quarter 2026 revenues were $58,581,520, compared with $43,353,235, and Net Income attributable to the company was $15,692,742.
  • Management services Revenue was $16,396,201, compared with $9,462,183, after fee revisions effective June 1 and July 1, 2026.
  • Cash and cash equivalents were $198,428,275 at September 30, 2026, compared with $163,773,838 at December 31, 2025.
  • The $20.0 million share repurchase program ends December 31, 2026, and no shares had been repurchased by September 30, 2026.

SBC Medical Group Holdings Incorporated (NASDAQ:SBC) shares were trading at USD 6.23 on November 17, 2026, up 0.81%, with a relative Volume at time of 1.96. The company, which manages cosmetic treatment centers mainly in Japan, acquired control of Waqoo on December 19, 2025, revised certain service fee structures in mid-2026, and filed its third quarter report on November 13.

SBC Medical Group Holdings Incorporated is a Delaware corporation with principal executive offices in Irvine, California. Its operating Subsidiary is a management company headquartered in Irvine and Tokyo that provides management services to cosmetic treatment centers mainly in Japan. Services include marketing, staff management, booking, equipment and consumables procurement, equipment rental, leasehold improvement and licensing of technologies and trademarks. It reports an SBC Core Segment and a Waqoo Segment, which sells medical support services and direct-to-consumer products. Its fiscal year ends December 31. The company has entered franchisor-franchisee and service contracts with seven medical corporations and other entities in Japan, which are related parties, as relatives of the CEO are members of their governing meetings.

Third Quarter Results

For the quarter ended September 30, 2026, SBC reported revenues of $58,581,520, compared with $43,353,235 a year earlier. Gross Profit was $42,179,020, compared with $30,611,487, and operating expenses were $15,761,753, compared with $14,730,247. Income from operations was $26,417,267, compared with $15,881,240.

Income tax expense was $9,378,075, compared with $5,673,538. Net income was $16,416,759, and net income attributable to the company was $15,692,742, or $0.15 per share, compared with $12,824,636, or $0.12. Adjusted EBITDA, a non-GAAP measure, was $27,594,226, compared with $16,627,451. The company stated that yen Depreciation reduced net revenues by $4,207,735 and net income by $1,391,504.

By stream, franchising revenue was $9,572,091, compared with $9,929,387, and procurement revenue was $14,174,222, compared with $13,406,905. Management services revenue was $16,396,201, compared with $9,462,183, and rental services revenue was $8,062,918, compared with $6,219,645. Waqoo Segment revenue was $5,554,162, with no comparable amount a year earlier. For the nine months, revenues were $150,830,150, compared with $134,040,783.

Balance Sheet, Cash Flow and Capital

Cash and cash equivalents were $198,428,275 at September 30, 2026, and working Capital was $199,190,891. Net cash provided by Operating Activities for the nine months was $50,247,388, compared with net cash used of $27,295,426, and net cash used in financing activities was $8,940,299, mainly repayments of borrowings.

On December 29, 2025, the board authorized a share repurchase program of up to $20.0 million that terminates on December 31, 2026. The company had repurchased no shares under it as of September 30, 2026. It holds about 18.2% of the voting interest in OT Midco, acquired for $20.3 million, and has committed to an additional $5 million Investment payable in December 2026 or another agreed month. The company stated that its cash, Operating Cash Flow and available bank borrowings should meet Working Capital needs for the next 12 months.

Legal Matter and Plans

A putative class action filed in February 2026 challenged a director removal provision in the certificate of incorporation. Stockholders approved eliminating the provision in July 2026, the action was dismissed as moot in October 2026, and the company paid a $50,000 mootness fee.

On its November 13, 2026 call, management said it will begin developing its own blood biomarker testing program in November 2026 and aims to establish a longevity center in 2027. The company did not provide numerical guidance. Management said it plans to roll out longevity initiatives in stages through 2028.